Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-562 in early course schizophrenia
NCT04457310Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of razpipadon in schizophrenia, sponsored by Yale University. Started Mar 2021; status: completed.
02
Drugs
razpipadon
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04457310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457310.